Beaumont V, Beaumont J L
Pathol Biol (Paris). 1985 Apr;33(4):245-9.
The ingestion of synthetic steroidal and non-steroidal estrogens may induce antiestrogen antibodies in women on oral contraceptives, and in prostatic patients treated with diethylstilbestrol (DES). Natural sex hormones have no such effect. A radioimmunoassay with tritiated ethinylestradiol or DES was applied to study the prevalence of synthetic sex hormone antibodies in 2 populations: 100 women on estroprogestative hormones and 93 cases of DES treated prostatic cancers. Homologous non-treated controls were compared. Results allowed to identify among treated and asymptomatic subjects an immunoreactive population of 30% women and 47% men. Furthermore, the antibodies were found with a much higher frequency (p less than 0.001) in patients who had experienced a thromboembolic disease while on treatment: 90% of women and 74% of men. The importance of these antibodies as a risk factor, their possible role in promoting vascular lesions, the interest of their detection for the prevention of the vascular risk induced by synthetic sex hormones, are considered.
口服合成甾体和非甾体雌激素可能会在服用口服避孕药的女性以及接受己烯雌酚（DES）治疗的前列腺疾病患者体内诱导产生抗雌激素抗体。天然性激素则无此作用。采用氚标记乙炔雌二醇或己烯雌酚的放射免疫分析法，研究了两类人群中合成性激素抗体的流行情况：100名服用雌激素孕激素的女性和93例接受DES治疗的前列腺癌患者。并与未接受治疗的同源对照组进行了比较。结果显示，在接受治疗且无症状的受试者中，可识别出免疫反应性人群，其中女性为30%，男性为47%。此外，在治疗期间发生过血栓栓塞性疾病的患者中，抗体出现频率更高（p<0.001）：女性为90%，男性为74%。文中探讨了这些抗体作为风险因素的重要性、它们在促进血管病变中可能发挥的作用，以及检测它们对于预防合成性激素诱导的血管风险的意义。
